PerkinElmer Elects Samuel Chapin to Board of Directors
PerkinElmer, Inc. announced that Samuel R. Chapin has been elected to the Company's Board of Directors.
"I am pleased to welcome Samuel to our Board, as he brings extensive experience in strategic advisory, mergers and acquisitions, and deal financing for a wide range of transactions, along with deep knowledge of the industrial marketplace," said Robert Friel, Chairman and Chief Executive Officer, PerkinElmer.
Chapin most recently served as Executive Vice Chairman of Global Corporate & Investment Banking for Bank of America Merrill Lynch, where he held the role since 2010 and was responsible for managing relationships with the firm's largest clients. He retired as of June 30, 2016.
Chapin was named Vice Chairman of Merrill Lynch & Co in September 2003 and was a member of the firm's executive Operating Committee. From 2001 to 2003, he was Senior Vice President and Head of the Global Investment Banking division. He previously led the investment banking group that covered industrial companies, actively managing the firm's relationships with clients in the industrial, resources and consumer products industries. He joined Merrill Lynch in 1984 as a member of the Mergers & Acquisitions group and was named a managing director in Corporate Banking in 1993. He has worked on a wide range of financings and strategic advisory assignments totaling over $500 billion. Chapin has also been named Investment Banker of the year by Investment Dealers' Digest.
Chapin received a Bachelor of Arts from Lafayette College and a Master of Business Administration, with distinction, from The Wharton School at the University of Pennsylvania. He also serves on the board of trustees at Lafayette College and is a director for the Wharton Financial Advisory Board. Chapin is also a member of the board of directors of the Roundabout Theatre Company.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.